Los Alamos National Laboratory has been applying biosurveillance expertise to the COVID-19 pandemic.
National Virtual Biotechnology Laboratory
The U.S. Department of Energy National Virtual Biotechnology Laboratory (NVBL) is a consortium of DOE National laboratories that was established in March 2020 to address key challenges associated with the COVID-19 crisis. Watch this video to learn more.
Diagnostics and Genomics
COVID-19 Genome Analytics website for sequence to genome tools, phylogeny-informed assay validation, and geographic analytics of COVID-19 cases.
SARS-CoV-2 sequence analysis pipeline for analyses and tools for exploring accruing mutations in the Spike protein of SARS-CoV-2.
Operated an FDA-CLIA registered COVID-19 diagnostic testing facility for LANL personnel and LANL subcontractor personnel.
Developed high-affinity antibody pairs for advanced diagnostic tools.
Evaluated various supply chain elements (viral transport media, assay kits, pooling strategies, reagents) to enhance diagnostic testing.
Provided bioinformatics expertise and support to partner labs worldwide that processed COVID-19 samples in their own countries.
Developed new tests that could screen for multiple respiratory pathogens at once.
Predictive Modeling and Decision Support
The Global Disease Modeling & Forecasting Center combined Los Alamos capabilities and key partnerships to develop, validate, and operationalize epidemiological models to combat infectious diseases.
COVID-19 Forecasted Case Data website tracked confirmed COVID-19 cases and deaths and forecasted spread.
Evaluated testing and diagnostic sensitivity and provided decision support analysis for testing diagnostics, strategy, and uncertainty at the metropolitan level—using Modeling Epidemics for Decision support and Infrastructure ANalysis (MEDIAN).
Worked with three other National Laboratories to provide situational awareness, predictive modeling, and a visualization portal to characterize the spread of COVID-19 across the United States.
Quantified how the SARS-CoV-2 virus behaves in the host organism.
Used bioinformatics and modeling to track the diversity of the pathogen and how it is evolving.
Developed models of various mitigation strategies to inform decision makers at the state and local level.
Modeled hospital/healthcare surge capacity in response to COVID-19.
Used models to evaluate critical healthcare supply chains.
Vaccines and Countermeasures
Worked on a T-cell response vaccine for SARS-CoV-2.
Investigated the interaction between SARS-CoV-2 and human receptors to develop lung-protective therapies.
Designed and synthesized surface proteins for drug studies.
Synthesized compounds for anti-viral drugs for the treatment of COVID-19.
Identified potential drug targets through structural and computational studies.